

## Information regarding proposed Board of Directors

### Thomas von Koch



**Proposed for re-election as Board Member and re-election as Chairman of the Board.**

<b>Year of birth</b>	1966
<b>Education/Experience</b>	BSc Business and Economics, Stockholm School of Economics, with two main subjects, Financial Economics and Accounting & Finance.
<b>Position in the Company</b>	Co-founder of Bactiguard and Chairman of the Board 2005–2015 and 2019–2023. Board Member and interim CEO since May 2023..
<b>Other significant positions</b>	Previously partner and CEO (2014-2018) of private equity firm EQT. Special advisor to EQT. Investor, owner and Board Member of A3P, Smartcella Holding AB and TomEnterprise AB.
<b>Holdings of securities in the company</b>	Class A shares: 2 000 000 (through legal entity). Class B shares: 4 604 182 (through legal entity and personal holdings). In addition 1 785 384 (holding per 31 March 2024) B shares are owned by an Endowment insurance, held by the company controlled by Thomas von Koch.
<b>Independence</b>	In his capacity as the Company's major shareholder and CEO, not independent in relation to the Company, Executive Management or the Company's major shareholders.
<b>Year elected to the Board of Directors</b>	2005 and 2019

## Professor Anna Martling



### Proposed for re-election as Board Member

<b>Year of birth</b>	1969
<b>Education/Experience</b>	MD, Ph.D, Karolinska Institutet, Board Certified Surgeon.  Dean Campus North, Karolinska Institutet, Member of the Faculty Board and Board of Research at Karolinska Institutet.
<b>Position in the Company</b>	Board member and member of the audit committee.
<b>Other significant positions</b>	Professor of Surgery, Karolinska Institutet, Senior Consultant Surgeon, Karolinska University Hospital and Scientific Director Life Science, Karolinska Institutet. Board Member of Radiumhemmets Forskningsfonder, Research!Sweden and Genomic Medicine Sweden.
<b>Holdings of securities in the company</b>	2,600 B-shares as personal holdings and 28,818 call options
<b>Independence</b>	Independent in relation to the Company, the management and the Company's major shareholders.
<b>Year elected to the Board of Directors</b>	2019

## Magdalena Persson



### Proposed for re-election as Board Member

<b>Year of birth</b>	1971
<b>Education/Experience</b>	<p>Master's degree in international economics and licentiate degree in industrial economics from Linköping University.</p> <p>Former CEO of Interflora and SamSari, as well as several roles within Microsoft and WM Data. Former Chairman of the Board of Affecto Plc, Nexon Asia Pacific and Iver Holding AB. Digitization as a core competence.</p>
<b>Position in the Company</b>	Board member and member of the remuneration committee
<b>Other significant positions</b>	Chairman of the Board of SK Shieldus (South Korea), Board Member of NCAB Group, Recover Nordic Group and Qarlbo AB, as well as advisor to private equity firm EQT.
<b>Holdings of securities in the company</b>	28,818 call options
<b>Independence</b>	Independent in relation to the Company, the management and the Company's major shareholders.
<b>Year elected to the Board of Directors</b>	2022

## Jan Ståhlberg



### Proposed for re-election as Board Member

<b>Year of birth</b>	1962
<b>Education/Experience</b>	<p>BSc Business and Economics, Stockholm School of Economics. Studies at the MBA program at New York University, Stern School of Business.</p> <p>Partner, Deputy CEO and Deputy Chairman of private equity firm EQT.</p>
<b>Position in the Company</b>	Board member, member of the remuneration committee and chairman of the audit committee.
<b>Other significant positions</b>	Board Member of Trelleborg AB and ITB-Med AB. Founder and CEO of Trill Impact AB.
<b>Holdings of securities in the company</b>	3,605,150 B shares as personal holdings
<b>Independence</b>	Independent in relation to the Company and management. Not independent in relation to the Company's major shareholders.
<b>Year elected to the Board of Directors</b>	2018

## Dr Richard Kuntz



**Proposed for re-election as a Board Member.**

**Year of birth**

1957

**Education/Experience**

Studies at Miami University, MD Case Western Reserve University School of Medicine. Residency/chief residency internal medicine at University of Texas Southwestern Medical School, Parkland Hospital. Fellowships cardiovascular diseases/interventional cardiology at Harvard Medical School and Beth Israel Hospital. MSc in Biostatistics Harvard T.H. Chan School of Public Health.

CMO/SO Medtronic PLC. Founder/CSO of Harvard Clinical Research Institute, Boston. Assoc. Professor of Medicine Harvard Medical School, Chief of Division of Clinical Biometrics, and Interventional Cardiologist of cardiovascular diseases division at Brigham and Women's Hospital, Boston.

**Position in the Company**

Board member

**Other significant positions**

Board Member of ZimVie Inc., Identiv Inc., and Cognito Therapeutics, Inc.

**Holdings of securities in the company**

121,655 call options

**Independence**

Independent in relation to the Company, the management and the Company's major shareholders.

**Year elected to the Board of Directors**

2023

*This is a translation of the Swedish version. In the event of deviations, the Swedish version available on the company's website applies, [www.bactiguard.com](http://www.bactiguard.com).*

*This document was last updated on: 10 April 2024*